Original title: Announcement of Renfu Pharmaceutical Group Co., Ltd. on the inclusion of the company’s products in the National Medical Insurance Catalog
Stock code: 600079 Stock abbreviation: Renfu Medicine Number: Lin 2021-119
Special Note
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and bear individual and joint responsibility for the authenticity, accuracy and completeness of the content.
According to the notice of the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security on the issuance of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)” (hereinafter referred to as the “National Medical Insurance Catalog”) (Medical Insurance Issue[2021]No. 50), the product injection of Yichang Renfu Pharmaceutical Co., Ltd. (hereinafter referred to as “Yichang Renfu”, the company holds 80% of its shares), a controlled subsidiary of Renfu Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”) Remazolam besylate and midazolam oral solution were successfully negotiated and included in the National Medical Insurance Catalog. The relevant information is hereby announced as follows:
1. Basic situation of drugs
2. Other relevant information about the drug
1. Yichang Renfu obtained the “Drug Registration Certificate” for remazolam besylate for injection in July 2020. The sales of this product in 2020 will be about 10 million yuan, and the sales in the first three quarters of 2021 will be about 40 million yuan. Yuan. This product belongs to category 1 of chemical drugs. It is a new type of benzodiazepine drug jointly developed by Yichang Renfu and PAION of Germany. It is an ultra-short-acting GABAa receptor agonist. The German company PAION submitted an application for procedural sedation indications for remazolam besylate to the European Medicines Agency (European Medicines Agency) in November 2019, and was approved for marketing in March 2021. Authorized by the German company PAION, the product was approved to be marketed in Japan for general anesthesia in January 2020, and was approved to be marketed in the United States in July 2020 for the induction and maintenance of procedural sedation.
2. Yichang Renfu obtained the “Drug Registration Certificate” for midazolam oral solution in May 2021, and the product has been on the market in the third quarter of 2021. This product belongs to the third category of chemical drugs. It is currently the exclusive product of Yichang Renfu in China. According to the website of the State Drug Administration, Xinjiang Tefeng Pharmaceutical Co., Ltd. has completed the pharmacokinetic clinical trial of midazolam oral solution in children. , Jiangsu Enhua Pharmaceutical Co., Ltd. is undergoing production review of midazolam hydrochloride syrup.
3. Impact on the company
This time, Yichang Renfu products remazolam besylate and midazolam oral solution for injection are included in the “National Medical Insurance Catalog”, which will benefit the market sales of the above products. As the “2021 National Medical Insurance Catalogue” will be officially implemented on January 1, 2022, this matter will not have a significant impact on the company’s operating performance during the reporting period. Investors are requested to invest rationally and pay attention to investment risks.
Special announcement.
Renfu Pharmaceutical Group Co., Ltd.
Board of Directors
Two 21st December 4th
.